Synergistic inhibition of breast cancer cell lines with the combination of a dual inhibitor of EGFR/HER-2/neu and a Bcl-2 inhibitor No significant financial relationships to disclose. This is an ASCO ...
Arsenic trioxide (ATO) has proven efficacy against acute promyelocytic leukaemia but faces considerable challenges in the treatment of solid tumours due to rapid systemic clearance, off-target ...
Safety and feasibility of JAK inhibitor ruxolitinib in newly-diagnosed high-grade gliomas (CRUX): Final toxicity report. Efficacy of function-enhanced, re-activatable, dual-specific CAR T cells ...
Early studies indicate oral arsenic trioxide provides similar systemic exposure to IV dosing. The Food and Drug Administration (FDA) has granted Fast Track designation to QTX-2101, an oral formulation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results